Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,800,103
  • Shares Outstanding, K 66,449
  • Annual Sales, $ 7,020 K
  • Annual Income, $ -157,860 K
  • EBIT $ -235 M
  • EBITDA $ -247 M
  • 60-Month Beta 1.13
  • Price/Sales 260.40
  • Price/Cash Flow N/A
  • Price/Book 3.06

Options Overview Details

View History
  • Implied Volatility 82.42% (-14.80%)
  • Historical Volatility 49.13%
  • IV Percentile 43%
  • IV Rank 29.66%
  • IV High 155.78% on 11/10/25
  • IV Low 51.48% on 01/17/25
  • Expected Move (DTE 3) 3.70 (13.85%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 19
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 4,235
  • Open Int (30-Day) 4,472
  • Expected Range 22.99 to 30.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.00
  • Number of Estimates 6
  • High Estimate -0.93
  • Low Estimate -1.03
  • Prior Year -0.71
  • Growth Rate Est. (year over year) -40.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.53 +8.81%
on 11/19/25
30.50 -12.49%
on 12/08/25
+1.14 (+4.46%)
since 11/14/25
3-Month
22.10 +20.77%
on 11/11/25
30.50 -12.49%
on 12/08/25
+2.11 (+8.58%)
since 09/16/25
52-Week
14.40 +85.35%
on 04/09/25
30.50 -12.49%
on 12/08/25
+0.49 (+1.87%)
since 12/16/24

Most Recent Stories

More News
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit...

CLDX : 26.68 (-1.51%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 26.68 (-1.51%)
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained...

CLDX : 26.68 (-1.51%)
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished...

CLDX : 26.68 (-1.51%)
Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim...

CLDX : 26.68 (-1.51%)
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition

--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today  positive data from...

CLDX : 26.68 (-1.51%)
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today  new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients...

CLDX : 26.68 (-1.51%)
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley...

CLDX : 26.68 (-1.51%)
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract Profound mast cell depletion did not result in improved clinical outcomes...

CLDX : 26.68 (-1.51%)
Celldex: Q2 Earnings Snapshot

Celldex: Q2 Earnings Snapshot

CLDX : 26.68 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 28.81
2nd Resistance Point 28.35
1st Resistance Point 27.72
Last Price 26.68
1st Support Level 26.64
2nd Support Level 26.18
3rd Support Level 25.55

See More

52-Week High 30.50
Last Price 26.68
Fibonacci 61.8% 24.35
Fibonacci 50% 22.45
Fibonacci 38.2% 20.55
52-Week Low 14.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar